CLINICAL EVALUATION: ENVIVE, a proprietary blend of 5 probiotic strains, was shown in a 30-day study of 188 participants to reduce the severity and frequency of 5 occasional GI symptoms (bloating, abdominal discomfort, gas, constipation, and diarrhea).1,*

SEVERITY: Mean symptom reduction1,†

  • ENVIVE reduced the SEVERITY of 5 occasional GI symptoms, including bloating, abdominal discomfort, gas, constipation, and diarrhea, as soon as 2 weeks
  • The mean reduction in symptom severity from baseline to week 4 ranged from 45% to 51% for every symptom except gas, where the mean reduction was 18%

FREQUENCY: Mean symptom reduction1,†


 
  • ENVIVE reduced the FREQUENCY of 5 occasional GI symptoms, including bloating, abdominal discomfort, gas, constipation, and diarrhea, as soon as 2 weeks
  • The mean reduction in symptom frequency from baseline to week 4 ranged from 39% to 46% for every symptom except gas, where the mean reduction was 24%

 

Study design: A 4-week clinical study of 188 adults who took ENVIVE once daily for 30 days. The primary endpoint was the percentage of participants with a positive end-of-study response for improvement in overall GI well-being. The secondary endpoints comprised outcomes for individual GI symptomatology, intestinal wall permeability, and quality of life. Overall GI well-being and patient satisfaction were evaluated on Day 30. GI symptom severity and frequency were measured at Day 1 (baseline), Day 14, Day 30, and Day 42. Severity was assessed using an 11-point scale (0=none, 10=severe). Frequency was assessed using a 5-point scale (0=never, 5=daily).1

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Positive participant experience1

In a 4-week clinical study of participants with symptoms of GI disturbances, the majority
had a positive experience after adding ENVIVE to their daily routines.

...

of participants reported improved
overall GI well-being1

Improvement in overall GI well-being was a primary endpoint in the 4-week clinical study.
 

 

Recommend once-daily ENVIVE

Request envive samples
OR sell in-office

Study design: A 4-week clinical study of 188 adults who took ENVIVE once daily for 30 days. The primary endpoint was the percentage of participants with a positive end-of-study response for improvement in overall GI well-being. The secondary endpoints comprised outcomes for individual GI symptomatology, intestinal wall permeability, and quality of life. Overall GI well-being and patient satisfaction were evaluated on Day 30. GI symptom severity and frequency were measured at Day 1 (baseline), Day 14, Day 30, and Day 42. Severity was assessed using an 11-point scale (0=none, 10=severe). Frequency was assessed using a 5-point scale (0=never, 5=daily).1

GI, gastrointestinal.

Secondary endpoint.

Reference: 1. Data on file. Bausch Health.